Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with crohn's disease

Digestive Endoscopy

Volumn 24, Issue 6, 2012, Pages 432-438

  Ono, Yoichiro ^a   Hirai, Fumihito ^a   Matsui, Toshiyuki ^a   Beppu, Takahiro ^a   Yano, Yutaka ^a   Takatsu, Noritaka ^a   Takaki, Yasuhiro ^a   Nagahama, Takashi ^a   Hisabe, Takashi ^a   Yao, Kenshi ^a   Higashi, Daijiro ^a   Futami, Kitaro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

avoidance of surgery; Crohn's disease; endoscopic balloon dilation; infliximab; intestinal stricture

Indexed keywords

INFLIXIMAB;

ARTICLE; BALLOON DILATATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPIC BALLOON DILATION; ENDOSCOPIC THERAPY; ENTERIC FEEDING; FEMALE; HEPATITIS B; HUMAN; IMMUNOMODULATION; INTESTINE STENOSIS; LONG TERM CARE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLEURISY; POST TREATMENT SURVIVAL; PULMONARY CRYPTOCOCCOSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHILD; CROHN DISEASE; DILATATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL OBSTRUCTION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867878823     PISSN: 09155635     EISSN: 14431661     Source Type: Journal    
DOI: 10.1111/j.1443-1661.2012.01315.x     Document Type: Article

References (41)

1. Targan SR, Hanauer SB, van Deventer SJH, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Engl. J. Med. 1997; 337: 1029-35.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: ACCENT 1 randomised trial. Lancet 2002; 359: 1541-9.
3. Rutgeerts P, Feagan BG, Lichtenstein GR, et al,. Comparison of scheduled and episodic treatment strategies of Crohn's disease. Gastroenterology 2004; 126: 402-13.
4. Present DH, Rutgeerts P, Targan SR, et al,. Infliximab for treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999; 340: 1398-405.
5. Sands BE, Anderson FH, Bernstein CN, et al,. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004; 350: 876-85.
6. Rutgeerts P, D'Haens G, Targan SR, et al,. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
7. Hanauer SB, Wagner CL, Bala M, et al,. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2004; 2: 542-53.
8. Lichtenstein GR, Yan S, Bala M, et al,. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
9. Feagan BG, Yan S, Bala M, Bao W, Lichteinstein GR,. The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol. 2003; 98: 2232-8.
10. Schnitzler F, Fidder H, Ferrante M, et al,. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
11. Rudolph SJ, Weinberg DI, McCabe RP, et al,. Long-Term durability of Crohn's disease treatment with infliximab. Dig. Dis. Sci. 2008; 53: 1033-41.
12. Holtmann M, Wanitscheke R, Helisch A, Bartenstein P, Galle PR, Neurath M,. Anti-TNF antibodies in the treatment of inflammatory intestinal stenosis in Crohn's disease. Z. Gastroenterol. 2003; 41: 11-7.
13. Sorrentino D, Avellini C, Beltram CA, Pasqual E, Zearo E,. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int. J. Colorectal Dis. 2006; 21: 276-81.
14. Prajapati DV, Saeian K, Kim JP, et al,. Symptomatic luminal stricture underlies infliximab non-response in Crohn's disease. Gastroenterology 2002; 122: A777.
15. Belaiche J, Louis E,. Early obstructive colon after treatment of active refractory Crohn's disease with infliximab. Gastroenterol. Clin. Biol. 2003; 27: 1045-7.
16. Lichtenstein GR, Olson A, Travers S, et al,. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am. J. Gastroenterol. 2006; 101: 1030-8.
17. Takagi S, Utsunomiya S, Kuriyama H, et al,. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment. Pharmacol. Ther. 2006; 24: 1333-40.
18. Sou S, Matsui T, Yao T, et al,. Clinical and endoscopic healing after infliximab treatment in patients with Crohn's disease. Dig. Endosc. 2006; 18: 29-33.
19. Hirai F, Beppu T, Nishimura T, et al,. Carbon dioxide insufflation compared with air insufflation in double-balloon enteroscopy: a prospective, randomized, double-blind trial. Gastrointest. Endosc. 2011; 73: 743-9.
20. Hirai F, Matsui T, Yao K, et al,. Efficacy of carbon dioxide insufflation in endoscopic balloon dilatation therapy using double balloon endoscopy. Gastrointest. Endosc. 2007; 66: S26-9.
21. Matsui T, Ikeda K, Tsuda S, et al,. Long-term outcome of endoscopic balloon dilation in obstructive gastrointestinal Crohn's disease: a prospective long-term study. Diagn. Ther. Endosc. 2000; 6: 67-75.
22. Hirai F, Beppu T, Sou S, et al,. Endoscopic balloon dilatation using double-balloon endoscopy is a useful and safe treatment for small intestinal strictures in Crohn's disease. Dig. Endosc. 2010; 22: 200-4.
23. Sands BE, Blank MA, Patel K, van Deventer SJ,. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study. Clin. Gastroenterol. Hepatol. 2004; 2: 912-20.
24. Gonzaga JE, Ananthakrishnan AN, Issa M, et al,. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm. Bowel Dis. 2009; 15: 1837-43.
25. Becker JM,. Surgical therapy for ulcerative colitis and Crohn's disease. Gastroenterol. Clin. North Am. 1999; 28: 371-90.
26. Mekhjian HS, Switz DM, Watts HD, Deren JJ, Katon RM, Beman FM,. National Cooperative Crohn's disease study: Factors determining recurrence of Crohn's disease after surgery. Gastroenterology 1979; 77: 907-13.
27. D'Haens G, van Deventer S, van Hogezand R, et al,. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-34.
28. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010; 15: 1385-95.
29. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al,. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8.
30. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M,. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007; 44: 265-7.
31. Ochenrider MG, Patterson DJ, Aboulafia DM,. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: Case report and literature review. Clin. Lymphoma Myeloma Leuk. 2010; 10: 144-8.
32. Ricart E, Panaccione R, Laftus EV, Tremaine WJ, Sandborn WJ,. Infliximab for Crohn's disease in clinical practice at the Mayo clinic: the first 100 patients. Am. J. Gastroenterol. 2001; 96: 722-9.
33. Su C, Lichtenstein GR,. Are there predictors of Remicade treatment success or failure? Adv. Drug Deliv. Rev. 2005; 57: 237-45.
34. Hirai F, Matsui T, Ishibashi Y, et al,. Asymptomatic pulmonary cryptococcosis in a patient with Crohn's disease on infliximab: case report. Inflamm. Bowel Dis. 2011; 17: 1637-8.
35. Vassalo R, Matteson E, Thomas CF Jr,. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to TNF alpha inhibition. Chest 2002; 122: 1093-6.
36. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R,. A novel anti-fibrotic agent pirfenidone suppresses TNF alpha at the translational level. J. Immunol. 2002; 169: 929-36.
37. Theiss AL, Simmons JG, Jobin C, Lund PK,. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J. Biol. Chem. 2005; 280: 36099-109.
38. Xu X, Rivkind A, Pikarsky A, Pappo O, Bischoff SC, Levi-Schaffer F,. Mast cells and eosinophils have a potential profibrogenic role in Crohn disease. Scand. J. Gastroenterol. 2004; 39: 440-7.
39. Vasilopoulos S, Kugathasan S, Saeian K, et al,. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. Am. J. Gastroenterol. 2000; 95: 2503.
40. Toy LS, Scherl J, Kornbluth A, et al,. Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: a series of a newly described complication. Gastroenterology 2000; 118: A2974.
41. Louis E, Boverie J, Dewit O, et al,. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg. 2007; 70: 15-9.